跳至主要内容
临床试验/CTRI/2024/05/067340
CTRI/2024/05/067340尚未招募2 期

Evaluation of The Individual and Combined Effect of Mritika Lepa and oral Ayurveda Drugs on Pain Alleviation and Modulation of Inflammatory Markers in Rheumatoid Arthritis A Pilot Clinical Study - nil

ational Institute of Ayurveda0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Patients aged 18 to 60 years of either sex
  • Confirmed and diagnosed cases of Rheumatoid Arthritis based on established criteria e g American College of Rheumatology/European League Against Rheumatism criteria
  • Active disease status as indicated by a Disease Activity Score DAS28 of more than or equal to 3 point 2
  • Chronic cases up to 5 years

排除标准

  • Pregnant or lactating individuals due to potential risks associated with the treatments
  • Known contraindications or allergy to any of the study drugs contents or Mritika Lepa
  • Presence of significant comorbidities such as uncontrolled diabetes hypertension renal or hepatic impairment which may interfere with the assessment of study outcomes
  • Coexistence of other autoimmune diseases
  • e g systemic lupus erythematosus that may confound the assessment of Rheumatoid Arthritis outcomes
  • Severe joint damage or deformities that may limit accurate pain assessment or interfere with the treatment outcomes
  • Use of systemic immunosuppressive agents within the last three months prior to enrolment
  • Recent major surgery within the last three months that may impact the study outcomes
  • Participation in another clinical trial within 30 days before screening
  • Inability to comply with the study procedures or follow-up visits

研究者

相似试验